1-<2-Chlor-ethylamino>-butan | 92177-54-3

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1-<2-Chlor-ethylamino>-butan
• 英文别名: butyl-(2-chloro-ethyl)-amine；1-Butylamino-2-chlor-aethan；Butyl-(2-chlor-aethyl)-amin；2-Butylamino-aethylchlorid；N-(2-chloroethyl)butan-1-amine
• CAS: 92177-54-3
• 化学式: C₆H₁₄ClN
• 分子量: 135.637
• InChiKey: WUDZNKRZCAILHY-UHFFFAOYSA-N

物化性质

• 沸点：
  113-116 °C(Press: 23 Torr)
• 密度：
  0.917±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  8
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-<2-Chlor-ethylamino>-butan 、 N-(3-Chlorformyloxy-phenyl)-carbaminsaeure-isopropylester 在 potassium carbonate 作用下， 以 水 、 乙酸乙酯 为溶剂， 生成 N-Isopropoxycarbonyl-3-anilin
  参考文献：
  名称：

  FR2272983

  摘要：

  公开号：
• 作为产物：
  描述：

  2-丁氨基乙醇 在 盐酸 作用下， 生成 1-<2-Chlor-ethylamino>-butan
  参考文献：
  名称：

  US2136171

  摘要：

  公开号：

文献信息

• New benzoic acid alkamine esters and a process for their manufacture
  申请人：HOECHST AG

  公开号：US02850497A1

  公开（公告）日：1958-09-02

  The invention comprises compounds of the general formula <;FORM:0797042/IV (b)/1>; (wherein R1 is an alkyl radical of 1 to 6 carbon atoms or a cycloalkyl or aralkyl radical, R2 and R3 are hydrogen atoms or alkyl, aralkyl or cycloalkyl radicals or together with the nitrogen atom represent the radical of a hydrogenated heterocyclic ring system, n is zero or 1 and X is a hydrogen atom or a hydroxyl group), and their preparation either by treating an ester or salt of 2-chloro-4-amino-benzoic acid with an alkylating, aralkylating or cycloalkylating agent to form the corresponding N-substituted compound and esterifying this with the appropriate basically substituted amino-alcohol or a hydrohalic acid ester thereof, or by treating an ester of 2-chloro-4-aminobenzoic acid with the appropriate basically substituted amino-alcohol or a hydrohalic acid ester thereof and then alkylating, aralkylating or cycloalkylating the nitrogen atom on the aromatic ring of the ester reaction product. The re-esterification in either process is carried out at elevated temperatures and in the presence of a metal alcoholate condensing agent. Alkylating agents referred to are alkyl halides, dialkyl sulphates or, preferably, aldehydes and hydrogen in the presence of a hydrogenation catalyst. In examples: (1) a mixture of 2-chloro-4-amino-benzoic acid ethyl ester, butyraldehyde and methanol is hydrogenated at 35 DEG C. in presence of Raney nickel to give 2-chloro-4-n-butylamino-benzoic acid ethyl ester, which is then heated at 120 DEG C. with dimethylamino-ethanol and sodium methylate solution to give 2 - chloro - 4 - n - butylamino - benzoic acid dimethylamino-ethyl ester, isolated as the hydrochloride; replacement of the dimethylamino - ethanol by 1 - dimethylamino - propane-diol-(2:3) gives 2-chloro-4-n-butylaminobenzoic acid - gamma - dimethylamino - beta - hydroxy-propyl ester hydrochloride; (2) replacement of butyraldehyde by propionaldehyde in the first stage of (1) gives 2-chloro-4-n-propylamino-benzoic acid ethyl ester which with dimethylamino-ethanol and, separately, 1-dimethylamino-propane-diol-(2:3) then gives the corresponding basic esters, isolated as hydrochlorides; (3) 2-chloro-4-n-butylamino-benzoic acid methyl ester, obtained as in (1), and morpholino-ethanol give 2-chloro-4-n-butylamino-benzoic acid morpholino-ethyl ester hydrochloride; (4) the corresponding piperidino compound is prepared similarly; (5) sodium in isopropanol is added to a solution of 2-chloro-4-n-butylamino-benzoic acid (prepared as the ethyl ester in (1)) in isopropanol, then n-butylamino-ethyl chloride is added and the whole is boiled, giving, on working up, 2-chloro-4-n-butylamino-benzoic acid n-butylaminoethyl ester hydrochloride; (6) 2-chloro-4-n-butylamino-benzoic acid dimethylaminoethyl ester hydrochloride is prepared as in (5); (7) dimethylaminoethanol and sodium methylate are heated under reduced pressure at 120 DEG C. with 2-chloro-4-amino-benzoic acid methyl ester giving 2-chloro-4-amino-benzoic acid dimethylaminoethyl ester, the hydrochloride of which on hydrogenation with butyraldehyde in presence of palladium gives the product of (6). A list of further starting materials, in which R1 has the additional values of methyl, ethyl, n-hexyl, cyclohexyl and benzyl and -NR1R2 has the additional values of amino, methylamino, mono- and di-n-propylamino, di - n - butylamino, n - hexylamino, cyclohexylamino, mono- and di-benzylamino, mono- and di-ethylamino and 1-pyrrolidino is given, and further salt-forming acids, including inorganic and organic acids, are also referred to. Specification 321,968, [Class 2 (iii)], is referred to.

  该发明涉及一般公式<;FORM:0797042/IV (b)/1>;的化合物（其中R1是1至6个碳原子的烷基基团或环烷基或芳基基团，R2和R3是氢原子或烷基、芳基或环烷基基团，或者与氮原子一起表示氢化杂环环系的基团，n为零或1，X为氢原子或羟基），以及它们的制备方法，可以通过处理2-氯-4-氨基苯甲酸的酯或盐与烷基化、芳基化或环烷基化试剂形成相应的N-取代化合物，并将其与适当的碱性取代的氨基醇或其氢卤酸酯酯化，或者通过处理2-氯-4-氨基苯甲酸的酯与适当的碱性取代的氨基醇或其氢卤酸酯酯化，然后在酯反应产物的芳香环上烷基化、芳基化或环烷基化氮原子。无论哪种方法中的再酯化都是在高温和金属醇酸酯缩聚剂存在的条件下进行的。所述的烷基化试剂是烷基卤化物、二烷基硫酸酯或更好地是醛和氢在氢化催化剂存在下。在示例中：（1）2-氯-4-氨基苯甲酸乙酯、丁醛和甲醇的混合物在Raney镍存在下在35摄氏度下加氢，得到2-氯-4-正丁基氨基苯甲酸乙酯，然后在120摄氏度下与二甲基氨基乙醇和甲基酸钠溶液反应，得到2-氯-4-正丁基氨基苯甲酸二甲基氨基乙酯，作为盐酸盐分离出来；将二甲基氨基乙醇替换为1-二甲基氨基-丙二醇-(2:3)得到2-氯-4-正丁基氨基苯甲酸-γ-二甲基氨基-β-羟基丙酯盐酸盐；（2）在（1）的第一阶段中用丙醛替换丁醛，得到2-氯-4-正丙基氨基苯甲酸乙酯，然后与二甲基氨基乙醇和分别与1-二甲基氨基-丙二醇-(2:3)反应，然后得到相应的碱性酯，作为盐酸盐分离出来；（3）在（1）中获得的2-氯-4-正丁基氨基苯甲酸甲酯和吗啉-乙醇反应，得到2-氯-4-正丁基氨基苯甲酸吗啉-乙酯盐酸盐；（4）相应的哌啶化合物类似地制备；（5）在异丙醇中加入钠溶液到2-氯-4-正丁基氨基苯甲酸的溶液（如（1）中制备的乙酯），然后加入正丁基氨基乙基氯化物，整个混合物煮沸，处理后得到2-氯-4-正丁基氨基苯甲酸正丁基氨基乙基酯盐酸盐；（6）2-氯-4-正丁基氨基苯甲酸二甲基氨基乙基酯盐酸盐的制备如（5）所述；（7）二甲基氨基乙醇和甲基酸钠在120摄氏度下减压加热，与2-氯-4-氨基苯甲酸甲酯反应，得到2-氯-4-氨基苯甲酸二甲基氨基乙酯，其盐酸盐在钯存在下与丁醛加氢反应，得到（6）的产物。还列出了进一步的起始材料，其中R1具有甲基、乙基、正己基、环己基和苄基的额外值，-NR1R2具有氨基、甲基氨基、单-和双正丙基氨基、双正丁基氨基、正己基氨基、环己基氨基、单-和双苄基氨基、单-和双乙基氨基和1-吡咯啉基的额外值，并且还提到了进一步的形成盐的酸，包括无机和有机酸。参考规范321,968，[类别2 (iii)]。
• Imidazo 4,5-C Pyridine Compounds and Methods of Antiviral Treatment
  申请人：Bondy S. Steven

  公开号：US20070244148A1

  公开（公告）日：2007-10-18

  The present invention relates to a pharmaceutical composition for the treatment or prevention of viral infections comprising as an active principle at least one imidazo[4,5-c]pyridine prodrug having the general formula (Z): The invention also relates to processes for the preparation of compounds according to the invention having above mentioned general formula and their use as a medicine or to treat or prevent viral infections.

  本发明涉及一种用于治疗或预防病毒感染的药物组合物，其包含至少一种具有以下通式（Z）的咪唑[4,5-c]吡啶前药作为活性成分：本发明还涉及制备符合上述通式的化合物的方法以及它们作为药物或用于治疗或预防病毒感染的用途。
• METHOD FOR HYDRATING LYOPHILIZED CYCLOPHOSPHAMIDE COMPOSITION AND PRODUCT THEREOF
  申请人：Sinotherapeutics Inc.

  公开号：EP3831366A1

  公开（公告）日：2021-06-09

  Provided are a hydration method for a lyophilized cyclophosphamide composition and a composition and preparation prepared thereby. The hydration method comprises: (a) providing an aqueous solution comprising cyclophosphamide and an optional pharmaceutically acceptable excipient; (b) freeze-drying the solution to obtain a lyophilized composition; and (c) hydrating the lyophilized composition by using liquid water to obtain the product.

  本发明提供了一种用于冻干环磷酰胺组合物的水合方法以及由此制备的组合物和制剂。水合方法包括：(a) 提供包含环磷酰胺和任选的药学上可接受的赋形剂的水溶液；(b) 冷冻干燥溶液以获得冻干组合物；(c) 使用液态水水合冻干组合物以获得产品。
• Kuznetsov,S.G., Journal of general chemistry of the USSR, 1961, vol. 31, p. 2449 - 2453
  作者：Kuznetsov,S.G.

  DOI：——

  日期：——
• DE1007335
  申请人：——

  公开号：——

  公开（公告）日：——